Novo Nordisk diabetes drug meets trial goals against insulin glargine
HQ Team January 9, 2023: Denmark’s Novo Nordisk declared its late-stage experimental once-weekly diabetes drug IcoSema achieved its primary endpoint of proving “non-inferiority” in.